Two Takayasu arteritis patients successfully treated with rituximab

Area of Science:

• Immunology
• Rheumatology
• Vascular Medicine

Background:

• Takayasu arteritis (TA) is a rare, chronic large vessel vasculitis affecting the aorta and its branches.
• The etiology of TA remains largely unknown, but B lymphocyte involvement is increasingly suspected.
• Refractory cases of TA pose significant treatment challenges.

Observation:

• Two patients with active, refractory Takayasu arteritis were treated with rituximab, an anti-CD20 monoclonal antibody.
• Rituximab targets B lymphocytes, a key component implicated in TA pathogenesis.
• Both patients experienced a favorable clinical response to the B cell depletion therapy.

Findings:

• B cell depletion therapy (BCDT) with rituximab demonstrated significant efficacy in managing refractory TA.
• The successful treatment of these two cases supports the role of B lymphocytes in TA.
• Rituximab offers a potential therapeutic option for patients with difficult-to-treat TA.

Implications:

• BCDT, specifically with rituximab, could be a valuable treatment strategy for refractory Takayasu arteritis.
• Further controlled clinical trials are warranted to evaluate the long-term efficacy and safety of BCDT in TA.
• Understanding the role of B cells in TA may lead to more targeted and effective therapies for this rare vasculitis.